Omicron - Good News Continues (60% Less Risk of Hospitalization by Omicron)

Omicron - Good News Continues (60% Less Risk of Hospitalization by Omicron as Compared to Delta - Studies roundup)

Let's review the latest studies about the risk of hospitalization, the severity of the disease, and the risk in previously infected, vaccinated vs. unvaccinated.

Buy me a coffee :-) https://www.buymeacoffee.com/DrMobeenSyed
Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true
Looking to support my educational work? Donate here: https://paypal.me/mobeensyed?locale.x=en_US

#drbeen #koolbeens #COVID

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

References Thursday, Dec. 23 2021 16:37 PM
HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung - News | HKUMed
https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection

Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland — University of Edinburgh Research Explorer
https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-

Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa | medRxiv
https://www.medrxiv.org/content/10.1101/2021.12.21.21268116v1

Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
https://www.medrxiv.org/content/10.1101/2021.12.21.21268116v1.full.pdf

Report 49 - Growth, population distribution and immune escape of Omicron in England | Faculty of Medicine | Imperial College London
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-49-Omicron/

Report 50 - Hospitalisation risk for Omicron cases in England | Faculty of Medicine | Imperial College London
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-50-severity-omicron/

2021-12-22-COVID19-Report-50.pdf
https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf

omicron spike protein less efficient gupta labs - Google Search
https://www.google.com/search?q=omicron+spike+protein+less+efficient+gupta+labs&ei=kAfFYf-vH8nVtAbCvZHgBA&ved=0ahUKEwj_t7P1ivv0AhXJKs0KHcJeBEwQ4dUDCA4&uact=5&oq=omicron+spike+protein+less+efficient+gupta+labs&gs_lcp=Cgdnd3Mtd2l6EAM6BwgAEEcQsAM6BQghEKABOgUIIRCrAkoECEEYAEoECEYYAFDYBVjuFmDpF2gBcAJ4AIABhgGIAY8IkgEDOC4zmAEAoAEByAEIwAEB&sclient=gws-wiz

Omicron Spike Protein is Less Efficient - Random COVID Questions with Dr. Been (#162) - YouTube
https://www.youtube.com/watch?v=Y7LNN0KF_Uk&ab_channel=DrbeenMedicalLectures

(22) Gupta Lab on Twitter: "Sharing some potentially significant findings relating to Omicron given the current situation. First of all huge thanks to the team working flat out- Bo Meng, @isabella_atmf and to our collaborators both in G2P, J2P along with @SystemsVirology. Findings as follows:" / Twitter
https://twitter.com/guptar_lab/status/1471941645797146628?s=21

Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa | medRxiv
https://www.medrxiv.org/content/10.1101/2021.12.19.21268038v1

Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa
https://www.medrxiv.org/content/10.1101/2021.12.19.21268038v1.full.pdf

Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests | OHSU News
https://news.ohsu.edu/2021/12/16/breakthrough-infections-generate-super-immunity-to-covid-19-study-suggests

Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection | Infectious Diseases | JAMA | JAMA Network
https://jamanetwork.com/journals/jama/fullarticle/2787447

Pfizer and BioNTech Provide Update on Omicron Variant | Pfizer
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant

Moderna - Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Preliminary-Booster-Data-and-Updates-Strategy-to-Address-Omicron-Variant/default.aspx